LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Aug 4, 2020 → Jul 14, 2023
NCT ID
NCT04501978About LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814 is a phase 3 stage product being developed by Eli Lilly for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04501978. Target conditions include Covid19.
What happened to similar drugs?
4 of 15 similar drugs in Covid19 were approved
Approved (4) Terminated (5) Active (8)
🔄Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + CorticosteroidGilead SciencesPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04501978 | Phase 3 | Completed |
Competing Products
20 competing products in Covid19